Drugs in Context (Aug 2024)

Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive and cognitive symptoms in schizophrenia, and dual psychosis

  • María Teresa Guarro Carreras,
  • Luis Jiménez Suárez,
  • Laura Lago García,
  • Laura Montes Reula,
  • Adrián Neyra del Rosario,
  • Francisco Acoidan Rodríguez Batista,
  • Miguel Velasco Santos,
  • Juan L Prados-Ojeda,
  • Marina Diaz-Marsà,
  • Manuel Martín-Carrasco,
  • Antonio Cardenas

DOI
https://doi.org/10.7573/dic.2024-4-4
Journal volume & issue
Vol. 13
pp. 1 – 18

Abstract

Read online

The management of schizophrenia necessitates a comprehensive treatment paradigm that considers individual patient nuances and the efficacy of lurasidone in addressing schizophrenia symptoms, particularly at elevated dosages. Numerous randomized trials have affirmed the efficacy of lurasidone across various dimensions of schizophrenia, demonstrating marked enhancements in positive, negative and cognitive symptoms compared to a placebo. In addition, lurasidone exhibits potential in ameliorating agitation amongst acutely ill patients, showcasing greater efficacy at higher doses. However, despite the favourable outcomes observed with higher lurasidone doses, routine clinical practice often opts for lower doses, potentially limiting its maximal therapeutic impact. Furthermore, lurasidone also shows efficacy in reducing post-psychotic depression in dual psychosis. Moreover, practical insights into lurasidone usage encompass swift dose escalation within a 1–5-day span and recommended combination strategies with other medications such as benzodiazepines for insomnia or agitation, beta-blockers for akathisia, and antihistamines or antimuscarinic drugs for patients transitioning rapidly from antipsychotics with substantial antihistamine and/or anticholinergic effects. Finally, a series of clinical cases is presented, highlighting benefits of lurasidone in terms of cognitive function, functional recovery and other therapeutic aspects for the management of schizophrenia.

Keywords